+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

From
Transdermal CNS Therapeutics to 2028 - Product Thumbnail Image

Transdermal CNS Therapeutics to 2028

  • Report
  • July 2023
  • 115 Pages
  • Global
From
Lupus Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Lupus Therapeutics - Global Strategic Business Report

  • Report
  • December 2025
  • 182 Pages
  • Global
From
From
From
From
Ulcerative Colitis Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Ulcerative Colitis Therapeutics - Global Strategic Business Report

  • Report
  • December 2025
  • 181 Pages
  • Global
From
From
Psoriasis Treatment Market - Global Forecast 2025-2032 - Product Thumbnail Image

Psoriasis Treatment Market - Global Forecast 2025-2032

  • Report
  • November 2025
  • 181 Pages
  • Global
From
Psoriasis Drugs Market - Global Forecast 2025-2032 - Product Thumbnail Image

Psoriasis Drugs Market - Global Forecast 2025-2032

  • Report
  • November 2025
  • 182 Pages
  • Global
From
From
From
Krabbe Disease Treatment - Global Strategic Business Report - Product Thumbnail Image

Krabbe Disease Treatment - Global Strategic Business Report

  • Report
  • December 2025
  • 194 Pages
  • Global
From
From
Chronic Plaque Psoriasis - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Plaque Psoriasis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator